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Abstract
Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a serious side effect of nitrogen-containing bisphosphonate
(NBP) use. Many studies have shown that BRONJ is limited to the jawbone and does not occur in the other bones. We
hypothesized that BRONJ is related to local bacterial iections and involves the innate immune system. To examine the
relationship between BRONJ and innate immunity, we examined the effects of NBPs on macrophages, one of the important
cell types in innate immunity. The expression of toll-like receptor-4 (TLR4) in cells after pretreatment with zoledronic acid
(ZOL) did not considerably differ from that in untreated control cells. However, cytokine levels and nitric oxide (NO)
production increased after pretreatment with ZOL. Furthermore, ZOL induced NF-kB activation by enhancing IkB-a
degradation. Lipopolysaccharide (LPS)-induced apoptosis also increased after pretreatment with ZOL. This effect was
mediated by a reduction of suppressor of cytokine signaling-1 (SOCS1), which is a negative regulator of myeloid
differentiation primary response gene 88 (MyD 88)-dependent signaling. These results suggest that ZOL induced excessive
innate immune response and proinflammatory cytokine production and that these processes may be involved in the bone
destruction observed in BRONJ.
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Introduction
Nitrogen-containing bisphosphonates (NBPs), which are syn-
thetic analogs of pyrophosphate, are an effective treatment for
osteoporosis, hypercalcemia of malignancy, osteolytic lesions in
multiple myeloma, and bone metastases from solid tumors,
including breast cancer and hormone-independent prostate cancer
[1,2]. In addition, NBPs are effective for the treatment of
numerous metabolic bone diseases. NBPs have a high affinity for
bone minerals [3] and accumulate in high concentrations in bones
[4,5]. They are selectively taken up by osteoclasts and strongly
inhibit bone resorption by inducing apoptosis in osteoclasts [6,7].
However, serious side effects such as bisphosphonate-related
osteonecrosis of the jaw (BRONJ) have been reported with the use
of NBPs [8,9]. In addition to the clinical appearance of exposed
necrotic bone, concomitant local infections are often observed in
patients with BRONJ. It has been reported that bisphosphonate-
related osteonecrosis is limited to the jawbone and is not observed
in other bones. In afflicted patients, BRONJ adversely affects
quality of life and produces significant morbidity. Because
bisphosphonates have been shown to reduce bone remodeling
[10] and angiogenesis [11], the suppression of bone turnover and
jaw angiogenesis resulting from bisphosphonates have been
proposed as underlying mechanisms for BRONJ.
Myriad numbers of bacteria reside in the mouth. Therefore, it
has been suggested that infection triggers the development of
BRONJ. Infections of the jawbone cause inflammation, which
intensifies as the severity of BRONJ increases [12]. Innate
immunity has a critical role in the inflammation process, and
innate immune surveillance relies in part on the recognition of
conserved molecules unique to some classes of potential pathogens.
For example, bacterial lipopolysaccharide (LPS), which is found in
the cell wall of Gram-negative bacteria, is a potent inducer of
immune responses. Toll-like receptors (TLRs), originally identified
as key mediators of development in Drosophila [13], initiate
second-messenger pathways that regulate the expression of genes
required for protective immune responses. For example, activation
through TLRs has been shown to induce potent inflammatory
responses, including the production of reactive oxygen and
nitrogen intermediates, the secretion of chemokines and cytokines,
and cellular differentiation, and many of these responses are
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regulated by NF-kB [14]. Each TLR has a specific ligand that
binds and activates it.
Depending on the oral cavity environment, the oral flora
changes in various ways. For example, when the oral cavity
environment gets worse, gingival inflammation occurs. As a result,
the proportion of Gram-negative bacteria producing LPS increase.
LPS-induced inflammatory cytokines specifically bind to TLR4.
Therefore, in this study, we used macrophages, which are of the
same origin as osteoclasts, like all typical immune cells, and we
focused on the relationship between innate immunity and
BRONJ, specifically the involvement of the NBP zoledronic acid




The murine macrophage cell line, RAW264.7, was obtained
from the Division of Host Defense, Research Center of Prevention
of Infectious Disease, Medical Institute of Bioregulation, Kyushu
University [15] and maintained in Dulbecco’s modified Eagle’s
medium (DMEM) (Sigma Aldrich, USA) supplemented with 10%
decomplemented fetal bovine serum, 2 mM glutamine, 1 mM
sodium pyruvate, 100 U/mL penicillin, and 100 mg/mL strepto-
mycin (Invitrogen, USA) in a humidified atmosphere containing
5% CO2 at 37uC.
Reagents
ZOL was purchased from Novartis Pharma AG (Switzerland) as
a hydrated disodium salt. Escherichia coli 0111: B4 LPS was
purchased from Sigma (UK).
Real-time Reverse Transcription-polymerase Chain
Reaction (RT-PCR)
RNA was extracted from RAW264.7 cells using TRIzol
Reagent (Invitrogen, USA) as according to the manufacturer’s
protocol. First-strand complementary DNA (cDNA) was synthe-
sized from total RNA (1.0 mg) in a final volume of 20 mL according
to the Reverse Transcriptase cDNA synthesis protocol. Quanti-
tative real-time PCR was performed with Brilliant III Ultra-Fast
SYBRH Green QRT-PCR Master Mix (Agilent Technologies,
USA). using the following gene-specific primers: mouse-IL-1b:
forward, CAGGATGAGGACATGAGCACC; reverse,
CTCTGCAGACTCAAACTCCAC; mouse-IL-6: forward, CCA-
GAGATACAAAGAAATGATGG; reverse, ACTCCAGAA-





dehyde 3-phosphate dehydrogenase (GAPDH): forward, CAATG-
CATCCTGCACCACCAA; reverse, GTCATTGAGAG-
CAATGCCAG. The specificities of the expected products were
demonstrated by melting curve analyses. GAPDH was used as an
internal standard for mRNA analysis. PCR reactions for each
sample were performed in triplicate. The real-time PCR data were
quantified by the DCT method using the following formula:
n = 100*2 - (DCT targeted gene - DCT GAPDH).
Quantification of Nitric Oxide (NO) Release
The accumulation of NO2
-, a stable end product extensively
used as an indicator of NO production by cultured cells, was
assayed using the Griess reaction kit (Dojindo Laboratories, Japan)
according to the manufacturer’s instructions. RAW264.7 cells
were plated in 96-well tissue culture plates at a density of 26103
cells per well (in 200 mL), and preincubated with or without ZOL
(10 mL) for 24 h, and then incubated with LPS (100 ng/mL) at
37uC for another 24 h. The cell-free supernatants were then
mixed with equal amounts of Griess reagent and incubated at
room temperature for 15 min, and then the absorbance at 540 nm
was read using a plate reader (Labsystems Multiscan MS,
Germany).
Flow Cytometry
RAW264.7 cells were plated in 6-well tissue culture plates at a
density of 26103 cells per well in DMEM with 10% fetal bovine
serum. After 24 h of culture, cells were incubated in the presence
or absence of 10 mM ZOL with or without 100 ng/mL LPS at
37uC for an additional 24, 48, or 72 h. Following bisphosphonate
treatment, RAW264.7 cells were harvested with 0.25% trypsin-
EDTA and then washed 3 times in phosphate-buffered saline.
Combined cell pools were finally resuspended in 250 mL of
labeling solution according to the manufacturer’s instructions and
then incubated for 10–15 min in the dark. Labeled cells were then
counted in a flow cytometer (FACS VerseTM; BD Biosciences,
USA) within 30 min. Annexin-V-fluorescein isothiocyanate
(FITC) labeling was measured at 518 nm in the FL-1 channel
(FITC detector), and propidium iodide (PI) staining was measured
at 620 nm in the FL-2-channel (phycoerythrin detector).
Western Blotting
RAW264.7 cells were incubated with ZOL in DMEM and 10%
fetal bovine serum for 24 h. After harvesting, whole cell lysates
were prepared by washing the cells 3 times with phosphate-
buffered saline and then resuspending them in lysis buffer (10 mM
Tris-HCl [pH 7.6], 150 mM NaCl, 1% Triton X-100, and a
cocktail of protease inhibitors; Boehringer Mannheim, Switzer-
land). Insoluble material was removed by centrifugation at
12,000 rpm for 10 min at 4uC. Samples containing equal protein
were mixed with 56 sample buffer (20% glycerol, 10% 0-
mercaptoethanol, 6% sodium dodecyl sulfate, and 125mM Tris-
HCl [pH 6.8]). Protein samples were separated with 10% sodium
dodecyl sulfate-polyacrylamide gel electrophoresis and then
transferred to polyvinyl difluoride membranes (Immobilon-P;
Millipore, USA). Membranes were blocked with blocking solution
(50 mM Tris-HCl, 150 mM NaCl, nonfat dry milk, and 0.1%
Tween) for 30 min at room temperature and then incubated
overnight with anti-phospho- IkB-a (#9246; Cell Signaling, USA),
anti- IkB-a (#9242; Cell Signaling, USA), anti-signal transducer
activator of transcription 1 (STAT1,#9172; Cell Signaling, USA),
anti-phospho-STAT1 (#9171; Cell Signaling, USA), anti-suppres-
sor of cytokine signaling 1 (SOCS1, ab65989; Abcam, USA), anti-
myeloid differentiation primary response gene 88 (MyD88,
ab2068; Abcam, USA), or anti-extracellular signal-regulated
kinase 2 (ERK2, #12607; Santa Cruz, USA) primary antibodies
at 4uC. The membranes were washed thoroughly with washing
buffer (0.32 M sucrose, 10 mM HEPES, and 0.1 mM EDTA
[pH 7.4]) and incubated with anti-rabbit IgG at a 1:10,000
dilution for 30 min. The proteins were visualized with SuperSignal
West Pico Chemiluminescent Substrate (Thermo Fisher Scientific,
USA) or Immobilon Western Detection Reagents (Millipore,
Germany).
Effect of Zoledronic Acid on TLR4 Signaling
PLOS ONE | www.plosone.org 2 July 2013 | Volume 8 | Issue 7 | e67906
Results
Effects of ZOL Pretreatment on LPS-induced Expression
of Cytokines
Interleukin (IL)-1b, IL-6, and tumor necrosis factor (TNF)-a are
important inflammatory cytokines. Therefore, we examined the
effects of ZOL on LPS-induced release of IL-1b, IL-6, and TNF-a
from RAW264.7 cells. RAW264.7 cells were pretreated with ZOL
(10 mM) for 24 h and then incubated with LPS (100 ng/mL) for 0,
1, 2, 4, or 6 h. LPS-stimulated production of IL-1b, IL-6, and
TNF-a from RAW264.7 cells increased significantly after ZOL
pretreatment (Figure 1).
Effects of ZOL on NO Release from LPS-stimulated
Macrophages
NO is an index of inflammation that is generated by iNOS. We
examined the effects of ZOL on LPS-induced iNOS release from
RAW264.7 cells. RAW264.7 cells were pretreated with ZOL
(10 mM) for 24 h and then incubated with LPS (100 ng/mL) for 0,
1, 2, 4, or 6 h. LPS-stimulated production of iNOS by RAW264.7
cells increased significantly after ZOL pretreatment (Figure 2A).
RAW264.7 cells were pretreated with ZOL for 24 h, and then
treated with LPS in the presence of ZOL for 24 h. NO production
was significantly higher in ZOL-pretreated cells than in the LPS-
treated controls, suggesting that ZOL accelerates NO release
(Figure 2B). ZOL had no effect on the release of NO (Figure 2B).
Effects of ZOL on LPS-induced Cell Apoptosis
Cells were stained with annexin-V-FITC and PI, and the results
are presented as contour plots of PI versus annexin-V staining
intensity (Figure 3A). The cells represented in the 4 quadrants of
these plots are as follows. The lower left includes cells that stained
negatively for both annexin-V and PI, and these were considered
undamaged cells. The lower right shows PI-negative cells with
moderate annexin-V staining, and these were considered early
apoptotic cells. The upper left includes annexin-V-negative cells
with high PI staining, and these were classified as necrotic cells.
The upper right includes cells that were both annexin-V and PI-
positive, and these were considered late apoptotic cells. These
results are expressed as the percentage of positively-stained
RAW264.7 cells (Figure 3A). The controls exhibited increased
apoptosis at 24 h followed by decreased apoptosis. After stimula-
tion with LPS, apoptosis increased compared to that of the
controls. The same degree of apoptosis was observed after LPS
stimulation with ZOL pretreatment, whereas a significant increase
in apoptosis was observed after further LPS stimulation (Figure 3B).
Effects of ZOL on LPS-induced TLR4-mediated Activation
of NF-kB
Translocation of NF-kB to the nucleus and its effects on
inflammatory genes are preceded by the phosphorylation,
ubiquitination, and proteasome degradation of IkB-a.
To determine whether ZOL has an effect on IkB-a phosphor-
ylation and its subsequent degradation, we examined the levels of
phospho-IkB-a and total IkB-a expression by western blotting.
RAW264.7 cells were pretreated with ZOL (10 mM) for 24 h and
then incubated with LPS (100 ng/mL) for 0, 15, 30, or 60 min.
After incubation, RAW264.7 cells were lysed and assayed by
western blotting using antibodies against phosphorylated IkB-a
and total IkB-a. These data indicated that ZOL treatment
increased the levels of phosphorylated IkB-a and enhanced the
degradation of IkB-a (Figure 4A).
TLR4 signaling is divided into MyD88-dependent and MyD88-
independent (Toll/IL-1 receptor-domain containing adaptor-
inducing and IFN-b-dependent) pathways. The MyD88-depen-
dent pathway mediates the expression of proinflammatory
cytokines, whereas the MyD88-independent pathway mediates
the induction of type-1 interferons and interferon-inducible genes.
TLR4 stimulation can induce potent responses, which explains
why inhibitory pathways are necessary to protect the host from
Figure 1. Effects of ZOL pretreatment on LPS-induced cytokine expression. RAW264.7 cells were cultured with or without ZOL for 24 h and
then with LPS for an additional 0, 1, 2, 4, or 6 h. After treatment, the expression of IL-1b, IL-6, and TNF-a was examined by real-time PCR. LPS-
stimulated inflammatory cytokine (IL-1b, IL-6, and TNF-a) production by RAW264.7 cells increased significantly after ZOL pretreatment. Significant
differences from the negative controls that were not treated with ZOL are indicated as follows: *P,0.05 and **P,0.01.
doi:10.1371/journal.pone.0067906.g001
Effect of Zoledronic Acid on TLR4 Signaling
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inflammation-induced damage. Some reports have suggested that
TLR4 signaling is regulated at multiple levels by numerous
negative regulators [16]. One negative regulator, SOCS1, induces
ubiquitination of the Toll/IL-1 receptor domain containing
adaptor protein, which is upstream of MyD88, and its subsequent
degradation. STAT1 is phosphorylated by Janus kinase/STAT
signaling, and induces SOCS1. SOCS1 is a negative feedback
regulator of signaling molecules such as LPS, and the induction of
SOCS1 expression can decrease macrophage cytokine production
[17]. In our studies, STAT1 protein levels decreased over time
after ZOL treatment. The levels of Phospho-STAT1 increased 1 h
after ZOL treatment and then decreased in a time-dependent
Figure 2. Effects of ZOL on NO release from LPS-stimulated macrophages. RAW264.7 cells were cultured with or without ZOL for 24 h and
then with LPS for an additional 0, 1, 2, 4, or 6 h. After treatment, iNOS expression was examined by real-time PCR. LPS-stimulated production of iNOS
from RAW264.7 cells increased significantly after ZOL pretreatment. Significant differences from the negative controls that were not treated with ZOL
are indicated by an asterisk (*P,0.05). (B) RAW264.7 cells were cultured with or without ZOL (10 mM) and LPS (100 ng/mL) for 24 h. NO release was
measured by the Griess method. NO production was significantly higher in ZOL-pretreated cells than in LPS-treated positive controls. ZOL had no
effect on the release of NO. Significant differences from the negative controls that were not treated with ZOL are indicated by an asterisk (*P,0.05).
doi:10.1371/journal.pone.0067906.g002
Figure 3. Effects of ZOL on LPS-induced cell apoptosis. RAW264.7 cells were incubated for the indicated times (0, 24, 48, or 72 h) with control
medium, LPS (100 ng/mL), ZOL (10 mM), or ZOL+LPS. annexin V and PI were added to the cultures prior to flow cytometry. See the methods for a
detailed explanation of the contour plots. (B) Plot of apoptosis in (m) controls, (N) LPS-treated, (%) ZOL-treated, and (&) ZOL+LPS-treated cells. After
stimulation with LPS, apoptosis increased compared to that in unstimulated controls. A similar amount of LPS-stimulated apoptosis was observed
after ZOL pretreatment, and a significant increase in apoptosis was observed after further LPS stimulation. Significant differences from the cikb
ontrols that were not treated with ZOL are indicated by an asterisk (*P,0.01).
doi:10.1371/journal.pone.0067906.g003
Effect of Zoledronic Acid on TLR4 Signaling
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manner. Therefore, the levels of SOCS1, whose expression is
induced by Phospho-STAT1, increased 1 h after ZOL treatment,
and then decreased in a time-dependent manner. MyD88 protein
levels increased over time after ZOL treatment (Figure 4B). These
results indicate that ZOL might be important for regulating
cellular SOCS1 accumulation.
Discussion
The accumulation of NBPs, which can decrease bone metab-
olism, does not properly induce tissue repair that normally occurs
in response to an induced or a physiological trauma, leading to the
exposure of necrotic bone to the oral environment [11,18,19].
A proposed hypothesis for the development of BRONJ is an
alteration in bone turnover associated with the particular
characteristics of the jaw bone [10,20], such as mucosal coating,
frequent risk of infection, and constant potential for trauma
[18,21]. Some authors have described the appearance of BRONJ
along with Actinomyces infections and have reported several cases
involving bone necrosis and osteomyelitis that were caused by this
microorganism [22].
However, there have been few reports on bacterial infection and
innate immunity in association with BRONJ. In our study, the
influence of ZOL, a NBP, on TLR4 signaling in RAW264.7 cells
was examined.
LPS binding to TLR4 induces inflammatory cytokines and
nitric oxide by activating NF-kB because intracellular signal
transduction through various TLR4 downstream adaptor mole-
cules occurs, resulting in the production of nitric oxide synthase.
We showed that LPS-stimulated induction of inflammatory
cytokines IL-1b, IL-6, and TNF-a and NO production in
RAW264.7 cells were enhanced after pretreatment with ZOL.
Although inflammatory cytokines in blood, such as TNF-a and IL-
6, are reportedly increased in patients treated with NBPs [23], we
did not find any significant increase in these inflammatory
cytokines in RAW264.7 cells after stimulation with ZOL alone.
Inflammation involves multiple cascades mediated by activated
inflammatory or immune cells. In these cascades, a number of
immunopathological changes occur, including the overproduction
of NO, proinflammatory cytokines such as IL-1b, IL-6, and TNF-
a, and other detrimental mediators, including caspases, that in
turn activate apoptosis [24,25].
TNF-a overproduction stimulates the generation of other pro-
oxidant mediators that directly induce cell injury. Among these,
free radicals such as NO seem to play a central role [26]. The
inflammatory cytokines IL-1b and TNF-a are involved in the
induction of cell apoptosis. IL-1b is produced as an inactive
precursor that assumes the active form through excision of a
precursor domain by an IL-1b-converting enzyme. This enzyme,
caspase 1, is the first caspase discovered and it is among a group of
cysteine proteases that govern the apoptotic process. TNF-a acts
as an apoptosis-inducing factor by activating caspase 8 through
adaptor molecules such as the TNF receptor type 1-associated
death domain molecule and the Fas-associated death domain
molecule [27]. It is known that NBPs induce cellular apoptosis by
inhibiting the mevalonic acid pathway [28,29]. In the present
study, apoptosis was increased by the administration of ZOL.
Furthermore, apoptosis in the ZOL-treated cells was highly
accelerated by stimulation with LPS. The inhibition of mevalonic
acid pathway by ZOL and the hypersecretion of inflammatory
cytokines in the ZOL-treated cells upon stimulation with LPS were
considered as the reason that apoptosis increased.
In TLR signal transduction, IkB-a is bound to NF-kB, which is
directly involved in the production of inflammatory cytokines;
thus, it acts as a suppressive factor [30]. Phosphorylation of IkB-a
at Ser 32 triggers its ubiquitination and subsequent proteolysis via
the proteasome pathway. NF-kB then translocates into the nucleus
and then inflammatory cytokines are expressed. In the present
study, inflammatory cytokine expression in ZOL-treated cells was
enhanced by increased translocation of NF-kB into the nucleus
due to elevated LPS-stimulated IkB-a phosphorylation and
accelerated proteolysis. IL-1 receptor-associated kinase M
(IRAK-M) and SOCS1 are known suppressors of this signal,
and they both inhibit the enzymatic activity of IRAK [17]. IRAK-
M is specifically expressed in monocytes and macrophages and is
induced through the NF-kB pathway [31]. IRAK-M inhibits the
formation of the IRAK-TRAF6 complex by suppressing the
dissociation of IRAK-1 and IRAK-4 from MyD88. SOCS1, a
cytokine-inducing protein with an SH2 domain, is induced by
TLR stimulation and inhibits the activation of NF-kB and
STAT1. It has been reported that, in the absence of SOCS1,
Figure 4. Effects of ZOL on LPS-induced TLR4-mediated activation of NF-kB cytokines. (A) RAW264.7 cells were cultured with or without
ZOL (10 mM) for 24 h and then with LPS (100 ng/mL) for the indicated times (0, 15, 30, or 60 min). The levels of phospho-IkB-a, IkB-a, and ERK2 were
analyzed by western blotting. These data indicated that ZOL treatment increased the levels of phosphorylated IkB-a and enhanced the degradation
of IkB-a. (B) RAW264.7 cells were cultured with ZOL for the indicated times (0, 1, 4, 8, or 12 h). STAT1 protein levels decreased over time after ZOL
treatment. The levels of Phospho-STAT1 increased 1 h after ZOL treatment and then decreased in a time-dependent manner. The levels of SOCS1,
which suppresses TLR4 signaling, increased 1 h after ZOL treatment and then decreased in a time-dependent manner. The levels of MyD88 protein
increased with time after ZOL treatment.
doi:10.1371/journal.pone.0067906.g004
Effect of Zoledronic Acid on TLR4 Signaling
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the inflammatory signals of IFN-c are excessively activated,
resulting in the disappearance of the suppressive effects of
prostaglandin E2 (PGE2) [32]. Therefore, excessive inflammation
might be provoked by suppression of the anti-inflammatory
actions of elements such as IRAK-M and SOCS1, and an
excessive inflammatory condition might develop due to suppres-
sion of the anti-inflammatory PGE2. It has also been reported that
IRAK-M and SOCS3 are attenuated by NBPs [33,34]. In our
study, SOCS1 expression was attenuated by ZOL alone, which
was similar to the results found with SOCS3. In addition, MyD88
expression increased, which was thought to be a result of
attenuated SOCS1 and IRAK-M expression due to stimulation
with BPs that downregulated their activation as part of a negative
feedback mechanism.
The results of this study have led us to speculate the mechanism
of BRONJ. BRONJ onset is thought to be associated with delay of
the physiological remodeling speed of the jawbone, the suppres-
sion of angiogenesis, delayed wound healing, and local bacterial
infections [35]. NBPs accumulate as bone is metabolized and their
potent suppression of osteoclasts leads to metabolic suppression in
bones throughout the body [4,5]. The concentration of NBPs is
selectively increased in bones where metabolism is naturally active.
The jawbone and in particular the alveolar bone, which is a
dental-supporting tissue, are constantly exposed to the strong
masticatory pressure that accompanies eating. For this reason, the
remodeling of the alveolar bone is faster than other bones in the
body. Due to the high rate of bone metabolism, NBPs selectively
accumulate in high concentrations in the alveolar bone area. In
addition, because the oral cavity has abundant bacterial flora, it is
easy to cause infection. Therefore, bone infections occur as the
bone becomes exposed due to surgical procedures and wounds.
Then, the high concentrations of NBPs are diffused from the
alveolar bone. Diffuse NBPs affects immune cells that have been
induced by the infection. As a result, immune cells produce large
amounts of inflammatory cytokines to give rise to a hyperin-
flammatory state. In the affected area, diffuse NBPs affects
fibroblasts and causes delayed wound healing [35], further
infection and aggravation of inflammation, which continues to
be repeated, extending the osteonecrosis. In the present study, the
inhibitory effects of ZOL on SOCS1 expression were first
confirmed in RAW264.7 cells. In conclusion, our data strongly
suggest that onset mechanism of BRONJ is due to the
dysregulation of the inflammatory cytokine output with ZOL.
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